United States AI in Drug Discovery and Development Market to hit US$ 34.05 Billion by 2033 | Top Companies 2025 - Alphabet (Google DeepMind), Atomwise Inc., BenevolentAI

"The Global AI in drug discovery and development market reached US$ 6.24 billion in 2024 and is expected to reach US$ 34.05 billion by 2033, growing at a CAGR of 18.5% during the forecast period 2025-2033." As per DataM intelligence research report

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/ai-in-drug-discovery-and-development-market?sp

United States: Recent Industry Developments

✅ In September 2025, Insilico Medicine launched an AI-driven platform to accelerate small molecule drug discovery. The system uses deep learning to predict molecular efficacy and toxicity. Early adoption shows faster lead identification and reduced R&D timelines.

✅ In August 2025, Atomwise expanded its AI-based drug discovery collaboration with major U.S. biotech firms. The platform screens billions of compounds for potential therapeutics. Initial projects demonstrate improved success rates and shorter preclinical phases.

✅ In July 2025, Recursion Pharmaceuticals introduced AI-assisted phenotypic screening tools for rare disease targets. The platform integrates imaging, omics data, and machine learning models. Early results highlight enhanced predictive accuracy and faster candidate selection.

✅ In June 2025, BenevolentAI partnered with pharmaceutical companies to implement AI for clinical trial optimization. The system predicts patient responses and identifies optimal biomarkers. Pilot programs indicate higher trial efficiency and improved outcome predictability.

Japan: Recent Industry Developments

✅ In September 2025, Astellas Pharma launched an AI-based platform for target identification and lead optimization in oncology. The system integrates genomic and chemical data for predictive modeling. Early use shows accelerated drug discovery cycles and higher success rates.

✅ In August 2025, Takeda Pharmaceutical implemented AI-assisted compound screening for immunology and rare disease therapeutics. The platform predicts bioactivity and potential adverse effects. Initial projects demonstrate faster lead prioritization and optimized experimental design.

✅ In July 2025, Daiichi Sankyo partnered with AI startups to enhance drug design and development for cardiovascular therapies. The initiative leverages machine learning to model molecular interactions. Early trials indicate improved prediction of compound efficacy and safety.

✅ In June 2025, Chugai Pharmaceutical introduced AI-powered platforms for clinical trial patient stratification and biomarker identification. The system analyzes multi-omics data to optimize trial design. Pilot programs report reduced recruitment times and improved trial outcomes.

AI in Drug Discovery and Development Market: Drivers

The AI in drug discovery and development market is experiencing rapid growth as pharmaceutical and biotechnology companies increasingly leverage artificial intelligence to accelerate the discovery of new therapeutics and optimize development pipelines. AI-powered platforms assist in target identification, compound screening, molecular modeling, and predictive toxicology, significantly reducing the time and cost associated with traditional R&D processes. Rising demand for personalized medicine, rare disease treatments, and faster drug approvals is driving adoption of AI solutions across preclinical and clinical research stages. Continuous advancements in machine learning, deep learning, and natural language processing are enhancing predictive accuracy, data integration, and decision-making. Integration with high-throughput screening, omics data, and real-world evidence is further expanding AI's utility in drug development.

Growing pressure to reduce R&D costs, improve success rates, and bring innovative therapies to market faster is fueling demand for AI-driven drug discovery solutions. Pharmaceutical companies are leveraging AI to analyze vast datasets, identify novel drug candidates, and optimize clinical trial design and patient stratification. Collaborative efforts between AI technology providers, research institutions, and biopharma companies are accelerating innovation and commercialization. Regulatory agencies are increasingly recognizing AI-assisted research for expedited review and approval processes. With its ability to enhance efficiency, precision, and predictive capabilities, AI is becoming an indispensable tool in modern drug discovery and development pipelines.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/ai-in-drug-discovery-and-development-market?sp

AI in Drug Discovery and Development Market: Major Players

Alphabet (Google DeepMind), Atomwise Inc., BenevolentAI, BioMap, BioSymetrics, DEEP Genomics, Euretos, Exscientia, IBM, and Iktos. Among others.

Segment Covered in the AI in Drug Discovery and Development Market:

➥ By Technology: Machine Learning, Natural Language Processing, Generative AI, Others

➥ By Application: Target Discovery & Validation, Hit Discovery & Virtual Screening, Screening, Hit-to-Lead, Lead Optimization, Pre-Clinical Testing, Clinical Trials, Others

Research Process:

Both primary and secondary data sources have been used in the AI in Drug Discovery and Development Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Most Frequently Asked Questions in the AI in Drug Discovery and Development Market Research Industry:

➠ Who leads the AI in Drug Discovery and Development industry and what's their competitive positioning regarding capacity, performance, and profitability?
➠ What growth opportunities and market challenges do AI in Drug Discovery and Development market vendors face?
➠ Which segments show the highest growth potential and market share distribution?
➠ What factors are driving or limiting AI in Drug Discovery and Development market growth?
➠ What are the dominant sales and distribution strategies in the AI in Drug Discovery and Development industry?

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=ai-in-drug-discovery-and-development-market

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.